Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedThe ClinicalTrials.gov data ingest modernization has been rescheduled to July 2025, and the study GLORIOSA has been updated with new details regarding its design and locations, including a significant increase in the number of participating sites.SummaryDifference100%
- Check18 days agoChange DetectedThe web page has been updated from version v2.16.2 to v2.16.3.SummaryDifference0.4%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check32 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check39 days agoChange DetectedThe webpage has been updated to reflect new study locations and contact information for a clinical trial related to ovarian cancer, including the addition of several hospitals in Japan and other countries. Additionally, the study's inclusion criteria have been revised, and the previous study details regarding Mirvetuximab Soravtansine have been removed.SummaryDifference8%
- Check174 days agoChange DetectedThe website has updated its contact information for study personnel, including new entries for Principal Investigators and their contact details, while removing previous listings and descriptions.SummaryDifference32%
Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.